The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. (Q51648841)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 March 2009

edit

Language	Label	Description	Also known as
English	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.	scientific article published on 18 March 2009

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

title

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

main subject

multiple sclerosis

0 references

patient

0 references

author

Michael Hutchinson

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Bianca Weinstock-Guttman

series ordinal

17

object named as

Bianca Weinstock-Guttman

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

Eva Havrdová

object named as

Eva Havrdova

series ordinal

7

0 references

Ludwig Kappos

series ordinal

2

object named as

Ludwig Kappos

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

Steven Galetta

series ordinal

6

object named as

Steven L Galetta

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

Gavin Giovannoni

series ordinal

5

object named as

Gavin Giovannoni

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

Peter Calabresi

series ordinal

3

object named as

Peter A Calabresi

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

David H. Miller

series ordinal

9

object named as

David H Miller

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Ernst-Wilhelm Radue

series ordinal

13

object named as

Ernst-Wilhelm Radue

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

AFFIRM and SENTINEL Investigators

series ordinal

21

object named as

AFFIRM and SENTINEL Investigators

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Richard A Rudick

series ordinal

14

object named as

Richard A Rudick

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Andrzej Wajgt

series ordinal

16

object named as

Andrzej Wajgt

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Michael A Panzara

series ordinal

20

object named as

Michael A Panzara

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

author name string

Christian Confavreux

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Fred D Lublin

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Paul W O'Connor

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

J Theodore Phillips

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Chris H Polman

series ordinal

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

William H Stuart

series ordinal

15

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Daniel R Wynn

series ordinal

18

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Frances Lynn

series ordinal

19

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

publication date

18 March 2009

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

published in

Journal of Neurology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

volume

256

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

page(s)

405-415

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

cites work

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

retrieved

21 January 2018

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

retrieved

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

retrieved

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

retrieved

21 January 2018

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathogenesis of multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of secondary-progressive multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axonal pathology in multiple sclerosis: relationship to neurologic disability

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19308305

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00415-009-0093-1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

Fatcat ID

release_le5znucdofhz3k2scxxlz5bry4

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/le5znucdofhz3k2scxxlz5bry4

retrieved

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

19308305

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19308305

retrieved

8 April 2018

reference URL

http://europepmc.org/abstract/MED/19308305

ResearchGate publication ID

24221544

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51648841&oldid=2211041648"